PMC full text:

Prostate. Author manuscript; available in PMC 2009 Sep 15.

Published in final edited form as:

Prostate. 2008 Sep 15; 68(13): 1477–1486.

doi: 10.1002/pros.20819

Copyright/LicenseRequest permission to reuse

Table 4

Associations of IGF1, IGFBP3 and IGF1:IGFBP3 with Risk of Clinical BPH, stratified by age in the PCPT

	Age 55–64 years				Age 65+ years
	Clinical Case (n=244)	Control (n=409)	OR (95% CI)¹		Clinical Case (n=164)	Control (n=295)	OR (95% CI)¹
IGF1 (ng/ml)				IGF1 (ng/ml)
Q1 <182.5	56	83	1.00	Q1 <156.3	28	58	1.00
Q2 182.5–<217.0	38	82	0.69 (0.41–1.16)	Q2 156.3–<197.7	41	60	1.49 (0.81–2.74)
Q3 217.0–<252.4	45	82	0.83 (0.51–1.37)	Q3 197.7–< 232.8	31	59	1.18 (0.62–2.22)
Q4 252.4–<304.9	57	80	1.08 (0.66–1.74)	Q4 232.8 – < 283.5	36	60	2.29 (0.69–2.24)
Q5 ≥ 304.9	48	82	0.89 (0.54–1.46)	Q5 ≥ 283.5	28	58	1.06 (0.56–2.03)
P trend			0.76				0.93

IGFBP3 (ng/ml)				IGFBP3 (ng/ml)
Q1 < 3685.4	68	83	1.00	Q1 < 3363.3	35	59	1.00
Q2 3685.4 – < 4199.8	46	81	0.71 (0.43–1.15)	Q2 3363.3 – < 3838.1	40	59	1.27 (0.70–2.29)
Q3 4199.8 – < 4653.3	52	81	0.79 (0.49–1.27)	Q3 3838.1 – < 4324.9	29	588	0.96 (0.51–1.79)
Q4 4653.3 – <5076.6	36	82	0.54 (0.33–0.90)	Q4 4324.9 – <5001.8	46	60	1.36 (0.77–2.42)
Q5≥ 5076.6	42	82	0.63 (0.38–1.03)	Q5 ≥ 5001.8	14	59	0.43 (0.21–0.89)
P trend			0.03				0.13

IGF1: IGFBP3 molar ratio				IGF1: IGFBP3 molar ratio
Q1 <.045	47	82	1.00	Q1 <.043	24	59	1.00
Q2 .045– <.051	31	82	0.67 (0.39–1.15)	Q2 0.43–<.051	35	60	1.43 (0.76–2.71)
Q3 .051–<.058	60	83	1.32 (0.80–2.16)	Q3 0.51 – < .056	38	59	1.63 (0.87–3.07)
Q4 .058–<.065	47	81	1.06 (064–1.78)	Q4 .056 – < 063	33	58	1.43 (0.75–2.73)
Q5 ≥ .065	59	81	1.32 (0.81–2.18)	Q5 ≥ 0.63	34	59	1.40 (0.74–2.66)
P trend			0.10				0.39

Open in a separate window

¹Adjusted for BMI and race. Quartile 1 is the referent for all models

-